US › Healthcare

20/20 Biolabs, Inc. Common Stock (AIDX)

US · Healthcare · Medical Devices

$0.46+7.09%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$353,375
Revenue YoY
-34.1%
Net profit
$-2.2M
Profit YoY
-74.1%
EPS
$-0.28
EPS estimate
$-0.10
Net margin
-615.4%

EPS came in at -0.28 against a street estimate of -0.10 — a miss of 180.0%.

Key statistics

Market cap
$5.2M
Forward P/E
0.0
P/B
2.05
Book value
$0.24
EPS (TTM)
$-0.49
52-week high
$50.00
52-week low
$0.40
50-day MA
$0.69
200-day MA
$1.88
Beta
-0.42

Analyst view

with an average price target of $5.00.

Shareholding

Insiders
26.16%
Institutions
2.73%

Largest institutional holders

FundStake
Cresset Asset Management, LLC2.16%
Citadel Advisors Llc0.13%
XTX Topco Ltd0.08%
UBS Group AG0.07%
McDonald Partners, LLC0.02%
Mccormack Advisors International0.01%
Toth Financial Advisory Corp0.00%
Hanson Mcclain Inc0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for 20/20 Biolabs, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.